TEL AVIV, Israel, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the Company will provide a corporate overview at two upcoming investor conferences in December.
Deutsche Bank Biofest | |
Date: | December 1 |
Time: | 5:10pm ET |
Location: | Four Seasons Hotel, Boston, MA |
26th Annual Piper Jaffray Healthcare Conference | |
Date: | December 3 |
Time: | 1:30pm ET |
Location: | New York Palace Hotel, New York City |
Webcast: | http://www.media-server.com/m/p/ix7mkwdj |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.